Head to Head Analysis: GRAIL (NASDAQ:GRAL) & Alector (NASDAQ:ALEC)

Alector (NASDAQ:ALEC) and GRAIL (NASDAQ:GRAL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Institutional & Insider Ownership

85.8% of Alector shares are held by institutional investors. 9.7% of Alector shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Alector has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, GRAIL has a beta of 4.31, suggesting that its share price is 331% more volatile than the S&P 500.

Profitability

This table compares Alector and GRAIL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alector	-156.03%	-123.02%	-27.48%
GRAIL	-329.86%	-16.64%	-14.02%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Alector and GRAIL, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	3	7	1	0	1.82
GRAIL	1	2	2	0	2.20

Alector presently has a consensus price target of $3.00, indicating a potential upside of 128.14%. GRAIL has a consensus price target of $70.00, indicating a potential downside of 17.87%. Given Alector’s higher probable upside, equities research analysts plainly believe Alector is more favorable than GRAIL.

Earnings & Valuation

This table compares Alector and GRAIL”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$100.56 million	1.43	-$119.05 million	($1.07)	-1.23
GRAIL	$125.60 million	24.46	-$2.03 billion	($13.11)	-6.50

Alector has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

About Alector

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

About GRAIL

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.